Clinical significance and prospects of using ST2 in isсhemic heart failure patients

Objective: The objective of this study is to assess the role of soluble ST2 (sST2) in developing adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5]-month follow-up period.

Results. Depending on the median of baseline sST2 levels, all patients were retrospectively divided into two groups: group 1 enrolled patients with sST2 levels < 31.5 ng/mL (n = 22); and group 2 comprised patients with sST2 levels ≥ 31.5 ng/mL (n = 26). In group 1, the sST2 levels were 27.27 [23.94; 29.23] ng/mL, which was 33.9% higher (p < 0.0000001) than in group 2 (41.28 [34.86; 50.17] ng/mL). ACEs were registered in 9 cases (40.9%) in group 1 and in 17 cases (65.4%) in group 2 (p = 0.025). Based on ROC-analysis, baseline ST2 levels ≥ 33.53 ng/mL were considered a biomarker to predict an unfavorable course of ischemic heart failure during 18 [12.5; 35.5] months of follow-up period with sensitivity of 78.9% and specificity of 62.2% (AUC 0.719; 95% CI 0.562–0.845; p = 0.0059).

Conclusion. The baseline sST2 levels may be considered a non-invasive biomarker allowing to predict the development of adverse cardiovascular events (ACE) and fatal outcomes in patients with chronic heart failure (HF) during 18 [12.5; 35.5] months of follow-up in addition to traditional risk factors.

1. Litvinenko A.A. Trends in population morbidity of cardiovascular diseases. The scientific community of students of the twenty-first century. Natural sciences: a collection of articles on the materials of the LI international student scientific-practical conference. 2016;4(50) (In Russ.). URL: https://sibac.info/archive/nature/4(50).pd.

2. Hamitova A.F., Rain S.S., Zagidullin S.Z., Ionin V.A., Gareeva D.F., Zagidullin N.S. Serum biomarkers in heart failure and cardiovascular mortality prediction. Arterial Hypertension. 2018;24(1):101–107 (In Russ.). DOI: 10.18705/1607-419X-2018-24-1-101-107.

3. Garganeeva A.A., Bauer V.A., Borel K.N. The pandemic of the XXI century: chronic heart failure is the burden of the modern society. Epidemiology (literature review). The Siberian Medical Journal. 2014;29(3):8– 12 (In Russ.). DOI: 10.29001/2073-8552-2014-29-3-8-12.

4. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7–13 (In Russ.). DOI: 10.15829/1560-4071-2016-8-7-13.

5. Borlaug B.A., Olson T.P., Lam C.S., Flood K.S., Lerman A., Johnson B.D. et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2010;56(11):845–854. DOI: 10.1016/j.jacc.2010.03.077.

6. Pocock S.J., Wang D., Pfeffer M.A., Yusuf S., McMurray J.J., Swedberg K.B. et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J. 2006;27(1):65–75. DOI: 10.1093/eurheartj/ehi555.

7. Belenkov Yu.N., Ageev F.T., Mareev V.Yu. Neurohormones and cytokines in heart failure: a new theory of the old disease? Russian Heart Failure Journal. 2000;1(4):135–138 (In Russ.).

8. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic and heart failure. Russian Journal of Cardiology. 2017;1:7–81 (In Russ.). DOI: 10.15829/1560-4071-2017-1-7-81.

9. Danielyan M.O. Prognosis and treatment chronic hear tfailure (during 20 years): Abstr. dis. … Cand. Med. Sci. Moscow, 2001:24 (In Russ.).

10. Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C. et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST elevation myocardial infarction. Circulation. 2008;117(15):1936– 1944. DOI: 10.1161/CIRCULATIONAHA.107.728022.

11. Broch K., Ueland Т., Nymo S.H., Kjekshus J., Hulthe J., Muntendam P. et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischemic etiology. Eur. J. Heart Fail. 2012;14:268–277. DOI: 10.1093/eurjhf/hfs006.

12. Felker G.M., Fiuzat M., Thompson V., Shaw L.K., Neely M.L., Adams K.F. et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ. Heart Fail. 2013;6(6):1172–1179. DOI: 10.1161/CIRCHEARTFAILURE.113.000207.

13. Gaggin H.K., Szymonifka J., Bhardwaj A., Belcher A., De Berardinis B., Motiwala S. et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65–72. DOI: 10.1016/j.jchf.2013.10.005.

14. O’Meara E., Prescott M.F., Rouleau J.L., Chiang L.-M., Solomon S.D., Swedberg K. et al. Association between sST2 Levels and Cardiovascular Outcomes and Effect of Sacubitril/Valsartan on sST2 Levels: Results from the PARADIGM-HF Trial. Journal of Cardiac. Failure. 2016;22(8):29–30.

15. Meijers W.C., de Boer R.A., van Veldhuisen D.J., Jaarsma T., Hillege H.L., Maisel A.S. et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur. J. Heart Fail. 2015;17(12):1271– 1282. DOI: 10.1002/ejhf.407.

16. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L., Vázquez R., Puig T., Valdés M. et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2009;54(23):2174–2179. DOI: 10.1016/j.jacc.2009.07.041.